Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2025-11-06 Earnings Release
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 6, 2025, announcing the financial results for the second quarter and half year ended September 30, 2025. It contains summarized financial highlights such as revenue, profit after tax, and EBITDA margin growth, along with business performance commentary. The document is titled as a media release and is addressed to stock exchanges for information and record. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR), but rather a summarized earnings announcement. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only.
2025-11-06 English
Outcome of meeting
Regulatory Filings
2025-11-06 English
General Updates
Regulatory Filings
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English
As per attachment
Regulatory Filings
2025-11-06 English
Investors Presentation
Investor Presentation Classification · 95% confidence The document is a presentation dated 6th November 2025 from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges, explicitly titled 'Presentation of Analyst / Institutional Investor Meetings'. It contains detailed slides about company leadership, commercial strategy, product portfolio, market performance, and financial highlights for Q2 FY 25-26. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal report or regulatory filing. There is no indication that this is an annual or quarterly report, audit report, or earnings release. The document is not a brief announcement or voting result, nor is it a legal or governance document. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (9394 characters) and detailed content support this classification with high confidence.
2025-11-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.